These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 12939723)

  • 21. Immunotoxins in cancer therapy: Review and update.
    Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
    Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotoxin therapy of cancer.
    Frankel AE
    Oncology (Williston Park); 1993 May; 7(5):69-78; discussion 79-80, 83-6. PubMed ID: 8512787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
    Mathew M; Verma RS
    Cancer Sci; 2009 Aug; 100(8):1359-65. PubMed ID: 19459847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal antibody therapy.
    O'Mahony D; Bishop MR
    Front Biosci; 2006 May; 11():1620-35. PubMed ID: 16368542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
    Pearson JW; Fogler WE; Volker K; Riggs CW; Gruys E; Groves ES; Wiltrout RH; Longo DL
    J Natl Cancer Inst; 1993 Jun; 85(11):907-12. PubMed ID: 8492319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale for the clinical use of immunotoxins: monoclonal antibodies conjugated to ribosome-inactivating proteins.
    Preijers FW
    Leuk Lymphoma; 1993 Mar; 9(4-5):293-304. PubMed ID: 8348066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotoxin: A new tool for cancer therapy.
    Allahyari H; Heidari S; Ghamgosha M; Saffarian P; Amani J
    Tumour Biol; 2017 Feb; 39(2):1010428317692226. PubMed ID: 28218037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal antibody-based therapies for hematologic malignancies.
    Multani PS; Grossbard ML
    J Clin Oncol; 1998 Nov; 16(11):3691-710. PubMed ID: 9817291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotoxins against solid tumors.
    Pirker R
    J Cancer Res Clin Oncol; 1988; 114(4):385-93. PubMed ID: 3045130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibodies and hematologic malignancies.
    Smith MR
    Cancer J; 2008; 14(3):184-90. PubMed ID: 18536558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bacterial Toxins for Cancer Therapy.
    Zahaf NI; Schmidt G
    Toxins (Basel); 2017 Jul; 9(8):. PubMed ID: 28788054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant immunotoxins for treating cancer.
    FitzGerald DJ; Kreitman R; Wilson W; Squires D; Pastan I
    Int J Med Microbiol; 2004 Apr; 293(7-8):577-82. PubMed ID: 15149034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids.
    Wenning LA; Murphy RM
    Biotechnol Bioeng; 1999 Mar; 62(5):562-75. PubMed ID: 10099565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Designing immunotoxins for cancer therapy.
    Pennell CA; Erickson HA
    Immunol Res; 2002; 25(2):177-91. PubMed ID: 11999171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells.
    Ochiai H; Archer GE; Herndon JE; Kuan CT; Mitchell DA; Bigner DD; Pastan IH; Sampson JH
    Cancer Immunol Immunother; 2008 Jan; 57(1):115-21. PubMed ID: 17634939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors.
    Duléry R; Ménard AL; Chantepie S; El-Cheikh J; François S; Delage J; Giannotti F; Ruggeri A; Brissot E; Battipaglia G; Malard F; Belhocine R; Sestili S; Vekhoff A; Delhommeau F; Reman O; Legrand O; Labopin M; Rubio MT; Mohty M
    Biol Blood Marrow Transplant; 2018 May; 24(5):1013-1021. PubMed ID: 29337223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
    Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
    Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
    Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
    Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel genetic immunotoxins and intracellular antibodies for cancer therapy.
    Chen SY; Marasco WA
    Semin Oncol; 1996 Feb; 23(1):148-53. PubMed ID: 8607024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin.
    Roy DC; Ouellet S; Le Houillier C; Ariniello PD; Perreault C; Lambert JM
    J Natl Cancer Inst; 1996 Aug; 88(16):1136-45. PubMed ID: 8757193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.